Intech Investment Management LLC Trims Stock Holdings in Abbott Laboratories $ABT

Intech Investment Management LLC lessened its stake in shares of Abbott Laboratories (NYSE:ABT) by 5.3% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 115,061 shares of the healthcare product maker’s stock after selling 6,499 shares during the quarter. Intech Investment Management LLC’s holdings in Abbott Laboratories were worth $15,411,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in ABT. Carr Financial Group Corp increased its holdings in Abbott Laboratories by 2.0% in the 3rd quarter. Carr Financial Group Corp now owns 3,880 shares of the healthcare product maker’s stock valued at $520,000 after purchasing an additional 76 shares during the last quarter. Tortoise Investment Management LLC grew its stake in shares of Abbott Laboratories by 10.7% in the second quarter. Tortoise Investment Management LLC now owns 795 shares of the healthcare product maker’s stock valued at $108,000 after buying an additional 77 shares in the last quarter. Gemmer Asset Management LLC raised its holdings in shares of Abbott Laboratories by 2.9% in the 3rd quarter. Gemmer Asset Management LLC now owns 2,750 shares of the healthcare product maker’s stock valued at $368,000 after buying an additional 78 shares during the period. Bridgewater Advisors Inc. boosted its holdings in Abbott Laboratories by 0.6% during the 2nd quarter. Bridgewater Advisors Inc. now owns 12,555 shares of the healthcare product maker’s stock valued at $1,607,000 after acquiring an additional 79 shares during the period. Finally, Global Financial Private Client LLC grew its position in Abbott Laboratories by 3.3% in the 3rd quarter. Global Financial Private Client LLC now owns 2,469 shares of the healthcare product maker’s stock valued at $331,000 after acquiring an additional 79 shares in the last quarter. 75.18% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Abbott Laboratories

In related news, Director Daniel J. Starks purchased 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 4th. The shares were purchased at an average cost of $108.73 per share, for a total transaction of $1,087,300.00. Following the purchase, the director directly owned 6,738,817 shares of the company’s stock, valued at $732,711,572.41. The trade was a 0.15% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.46% of the stock is owned by company insiders.

Abbott Laboratories Stock Up 1.3%

Shares of NYSE ABT opened at $116.21 on Friday. The business has a 50-day moving average of $117.53 and a two-hundred day moving average of $125.41. The company has a market capitalization of $201.94 billion, a price-to-earnings ratio of 31.24, a price-to-earnings-growth ratio of 1.83 and a beta of 0.75. Abbott Laboratories has a 1 year low of $105.27 and a 1 year high of $141.23. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.58 and a quick ratio of 1.24.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, hitting the consensus estimate of $1.50. The business had revenue of $11.46 billion for the quarter, compared to analyst estimates of $11.80 billion. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.The business’s quarterly revenue was up 4.4% on a year-over-year basis. During the same quarter last year, the company earned $1.34 EPS. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, analysts forecast that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be issued a $0.63 dividend. The ex-dividend date is Wednesday, April 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.2%. Abbott Laboratories’s dividend payout ratio is presently 67.74%.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the stock. Raymond James Financial lowered their price objective on shares of Abbott Laboratories from $146.00 to $130.00 and set an “outperform” rating for the company in a research note on Friday, January 23rd. Barclays decreased their price target on shares of Abbott Laboratories from $169.00 to $142.00 and set an “overweight” rating for the company in a research report on Monday, February 2nd. The Goldman Sachs Group cut their price objective on Abbott Laboratories from $152.00 to $140.00 and set a “buy” rating on the stock in a research report on Friday, January 23rd. Oppenheimer lowered their target price on Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating for the company in a research note on Friday, January 23rd. Finally, Daiwa Securities Group reduced their price target on Abbott Laboratories from $136.00 to $113.00 and set an “outperform” rating on the stock in a research report on Friday, January 30th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $137.05.

Key Stories Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Analyst/bullish research: A Seeking Alpha piece argues Abbott’s recent pullback is a buying opportunity, citing attractive profitable-growth characteristics and positioning for recovery. Abbott’s Meltdown Is Worth Buying
• Positive Sentiment: Income and steady growth pitch: The Motley Fool highlights Abbott as a steady income stock with double‑digit earnings growth and a dependable dividend, supporting longer-term total‑return appeal. Forget Tilray: This Steady Income Stock Beats Wild Cannabis Swings Every Time
• Neutral Sentiment: Valuation snapshot shows mixed signals: A Yahoo Finance valuation piece notes short‑term momentum has been weak and longer‑term returns negative, leaving conflicting “fair value” signals for investors to reconcile. Assessing Abbott Laboratories (ABT) Valuation
• Neutral Sentiment: Peer comparison: Coverage comparing Abbott to Intuitive Surgical frames Abbott as the steadier, dividend‑paying medtech pick, while Intuitive may offer higher growth from procedural/robotics expansion — useful for portfolio allocation but not an immediate earnings shock. Intuitive Surgical or Abbott: Which MedTech Stock Is a Better Bet Now?
• Neutral Sentiment: Sector noise from diagnostics peers: A large drop in Grail’s stock after trial updates is creating headline risk for diagnostics names; this may press sentiment in the broader diagnostics/medtech complex but does not directly change Abbott’s fundamentals. Grail’s Stock Dropped 50% on Friday
• Negative Sentiment: Underperformance and analyst skepticism: Multiple pieces note ABT has underperformed the Nasdaq and that some research houses have trimmed price targets and flagged execution/earnings-translation risk — pressure that can weigh on sentiment until clarity on growth drivers. Is Abbott Laboratories Stock Underperforming the Nasdaq?
• Negative Sentiment: Split analyst views driving volatility: A market narrative piece documents a wide range of recent price‑target moves (some cuts, at least one raise into the mid‑$150s), leaving investors with conflicting signals and more volatile price action. How The Evolving Wall Street Narrative Is Reframing Abbott Laboratories (ABT) Valuation Prospects

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.